Bumpus Namandje
SEC CIK 2060594 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | Dir | 127.6K | — | $28.1K | 5 | 2025-03-17 | 2026-06-18 |
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-22 16:32 | 2026-06-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Dir | A - Grant | $0.00 | +88.4K | 131.6K | +205% | $0 |
| T | 2026-06-22 16:32 | 2026-06-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Dir | S - Sale | $3.18 | -3,963 | 127.6K | -3% | -$12.6K |
| T | 2026-06-04 17:04 | 2026-06-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Dir | S - Sale | $3.54 | -4,386 | 43.2K | -9% | -$15.5K |
| D | 2025-06-23 | 2025-06-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Dir | A - Grant | $0.00 | +11.0K | 47.6K | +30% | $0 |
| D | 2025-03-19 | 2025-03-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Dir | A - Grant | $0.00 | +36.5K | 36.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations